Condition

ctDNA clinical trials and research

• 11Clinical trials
• 18NIH research projects
• 1New in 30 days
• 3Countries

Newest ctDNA clinical trials

All recruiting trials (11)

• ctDNA methylation-guided adjuvant therapy after removing colorectal liver metastases

  This trial tests whether using a blood test that detects ctDNA methylation after surgery can guide adjuvant therapy for patients who had colorectal cancer spread to the liver and were operated on with no remaining disease.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07917104

• Using plasma ctDNA methylation to guide adjuvant chemotherapy for high-risk T3N0 colorectal cancer

  This will test whether a blood ctDNA methylation test can help choose stronger chemotherapy after surgery for people with high-risk T3N0 (stage II) colorectal cancer who are ctDNA-positive one month after surgery.

  Recruiting Phase 2 Fudan University · Shanghai · NCT07562711

• Plasma ctDNA methylation-guided adjuvant chemotherapy for stage I / low-risk stage II colorectal cancer

  This trial will test whether using a blood test for ctDNA methylation one month after surgery to guide adjuvant chemotherapy (such as capecitabine) helps clear ctDNA and lower recurrence risk in adults with stage I or low-risk stage II colorectal cancer who are ctDNA-positive.

  Recruiting Phase 2 Fudan University · Shanghai · NCT07562659

• Plasma ctDNA methylation-guided adjuvant chemotherapy for people with T4N0 and low‑risk stage III colorectal cancer.

  This trial will test whether using a blood test (plasma ctDNA methylation) to guide 3 vs 6 months of adjuvant chemotherapy or to switch regimens helps people with T4N0 or low‑risk stage III colorectal cancer after surgery.

  Recruiting Phase 2 Fudan University · Shanghai · NCT07562503

• Plasma ctDNA methylation–guided adjuvant chemotherapy for high-risk stage III colorectal cancer

  This trial will test whether adding bevacizumab to standard FOLFOX or CAPOX chemotherapy based on plasma ctDNA results helps adults with high-risk stage III colorectal cancer (T4N+ or T1-3N2).

  Recruiting Phase 2 Fudan University · Shanghai · NCT07562490

• Using blood ctDNA changes to guide treatment for HER2‑negative metastatic breast cancer

  This study will try using early drops in circulating tumor DNA (ctDNA) after two cycles of antibody‑drug conjugate therapy to decide whether to intensify treatment for people with HER2‑negative metastatic breast cancer.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07394218

• Blood test using cfDNA methylation to screen for biliary tract cancers

  This study tests whether a blood test that reads cfDNA methylation can detect biliary tract cancers early in adults with or suspected of having these cancers.

  Recruiting Shanghai Jiao Tong University School of Medicine · Shanghai, Shanghai Municipality · NCT07176962

• Stereotactic body radiotherapy (SABR) for limited metastases

  This program tries stereotactic body radiotherapy (SABR) in people with up to five oligometastatic or oligoprogressive cancer lesions to see if it controls disease better, affects symptoms and side effects, and changes ctDNA in the blood.

  Recruiting Samsung Medical Center · Seoul · NCT07121335

• Evaluating ctDNA Changes After Chemotherapy and Radiotherapy for Esophageal Cancer

  This study is testing if a new treatment after chemotherapy and radiotherapy can help people with advanced esophageal cancer by looking at changes in their tumor DNA to see how well the treatment is working.

  Recruiting at 2 sites The Central Hospital of Lishui City · Jinhua, Zhejiang and 1 other locations · NCT06792786

• French test of leftover tumor DNA in the blood after pancreatic cancer surgery

  This will test whether a blood test for tumor DNA after surgery or after adjuvant chemotherapy can find pancreatic cancer patients at high risk of relapse.

  Recruiting University Hospital, Montpellier · Montpellier, Hérault · NCT06287749

• ctDNA blood tests to guide treatment in colorectal cancer with liver metastases

  A study using blood tests that look for tumor DNA to help decide which patients with colorectal cancer that has spread to the liver need more treatment after surgery.

  Recruiting at 2 sites University Hospital, Montpellier · Montpellier and 1 other locations · NCT06287723

NIH-funded research (18)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• Predicting PARP inhibitor response in advanced prostate cancer using PARP1 PET imaging and ultra-sensitive ctDNA

  A multi-center study aims to help determine which men with advanced prostate cancer will benefit from PARP inhibitor therapy using advanced PET imaging and ultra-sensitive blood tests.

  NIH research Washington University · Saint Louis, United States · NIH-11448789

• Multi-omic liquid biopsy to guide immunotherapy in colorectal and anal cancers

  A patient-facing overview of a study testing blood-based biomarkers (ctDNA and extracellular RNA) to better tailor immunotherapy for colorectal and anal cancer patients.

  NIH research University of Tx Md Anderson Can Ctr · Houston, United States · NIH-11415692

• ctDNA biomarker to guide safety of cancer immunotherapy in inflammatory arthritis

  A patient-facing biomarker study using a blood test to detect tumor DNA in people with cancer who develop inflammatory arthritis from immunotherapy, to help doctors pick safer treatment choices.

  NIH research Hospital for Special Surgery · New York, UNITED STATES · NIH-11411495

• H3K27M ctDNA Test for Tracking Diffuse Midline Glioma

  A minimally invasive blood or CSF test is being developed to detect a specific cancer marker and monitor brain tumor growth in children with DMG.

  NIH research University of Michigan at Ann Arbor · Ann Arbor, United States · NIH-11401915

• ctDNA biomarker test and use in care for young people with sarcomas

  A physician-scientist will study a blood-detected DNA marker (ctDNA) to guide treatment decisions for adolescents and young adults with sarcoma.

  NIH research Dana-Farber Cancer Inst · Boston, United States · NIH-11369672

• Blood test to detect resistance to hormone therapy in advanced prostate cancer

  This project tests a new blood-based DNA test to spot early resistance to androgen (hormone) therapies in men with advanced prostate cancer.

  NIH research Washington University · Saint Louis, United States · NIH-11231709

• Fast, easy, ultra-sensitive KRAS blood test using CRISPR and microscopy

  This project builds a quick, simple blood test to find tiny amounts of KRAS mutations in people with cancer so doctors can choose treatments and monitor response.

  NIH research University of Illinois at Urbana-Champaign · Champaign, United States · NIH-11160539

• Using tumor DNA to guide care for young adults with sarcomas

  This project looks at tiny pieces of tumor DNA in the blood to help doctors make better treatment plans for adolescents and young adults with sarcomas.

  NIH research Dana-Farber Cancer Inst · Boston, United States · NIH-11159471

• Understanding how blood tests and scans show treatment response in metastatic breast cancer

  This project looks at how changes in blood markers and specialized scans can show if treatment is working for people with metastatic breast cancer that has spread to the bones.

  NIH research University of Washington · Seattle, United States · NIH-11095754

• New blood test to detect treatment resistance in advanced prostate cancer

  This study is testing a new blood test called EnhanceAR-Seq that helps find out if metastatic prostate cancer is not responding to treatments earlier than current methods, so patients can get the right care sooner.

  NIH research Washington University · Saint Louis, United States · NIH-10995319

• Combining blood tests and MRI to predict treatment response in early breast cancer

  This study is looking at how using blood tests to check for cancer DNA along with MRI scans can help doctors see how well early breast cancer patients are responding to their chemotherapy before surgery, so they can make better treatment decisions and improve outcomes for everyone involved.

  NIH research University of California, San Francisco · San Francisco, United States · NIH-10983795

• Evaluating blood tests and immunotherapy for colorectal and anal cancers

  This study is exploring new blood tests to see how well patients with colorectal and anal cancers might respond to immunotherapy, helping doctors make better treatment choices and potentially offering access to the latest therapies for those who join.

  NIH research University of Tx Md Anderson Can Ctr · Houston, United States · NIH-10942040

• Evaluating blood and imaging tests to measure treatment response in metastatic breast cancer with bone involvement

  This study is looking at how tracking changes in tumor DNA and using special imaging can help us understand how well treatment is working for people with breast cancer that has spread to the bones, so we can better predict their health outcomes.

  NIH research University of Washington · Seattle, United States · NIH-10910869

• Detecting cancer through blood samples by identifying KRAS mutations

  This study is looking at how to better find cancer by checking for specific changes in a gene called KRAS in blood samples, which could help catch cancer earlier and more accurately with just a simple blood test.

  NIH research Duke University · Durham, United States · NIH-10906953

• Detecting cancer-related DNA in blood quickly and easily using advanced technology

  This study is testing a new, easy blood test that can find tiny pieces of cancer DNA in your blood, helping doctors see how your cancer is doing and decide on the best treatment for you.

  NIH research University of Illinois at Urbana-Champaign · Champaign, United States · NIH-10896361

• Affordable blood tests for managing lung cancer treatment

  This study is testing a quick and affordable blood test that looks for specific genetic changes in patients with non-small cell lung cancer to help doctors choose the best treatment for them and keep track of how well it’s working.

  NIH research Stanford University · Stanford, United States · NIH-10888192

• Using blood tests to improve treatment for young adults with sarcomas.

  This study is looking at how a blood test that checks for tumor DNA can help doctors make better treatment choices for teenagers and young adults with sarcomas, aiming to improve their care and reduce side effects.

  NIH research Dana-Farber Cancer Inst · Boston, United States · NIH-10865581

• Investigating factors that affect blood tests for early breast cancer detection

  This study is looking at how different ways of collecting and processing blood samples can help improve blood tests that check for early signs of breast cancer, and it's for patients with early or locally advanced breast cancer.

  NIH research University of Wisconsin-Madison · Madison, United States · NIH-10691211

Related topics

Quick answers

How many ctDNA clinical trials are recruiting right now?

11, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 3 countries. The most sites are in China (8 trials), France (2 trials), South Korea (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 6. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →